NgoJulayi 27, 2023, uLilly wabhengeza ukuba isifundo seMount-3 seTirzepatide sokunyanga izigulana ezityebileyo kunye nophononongo lweMount-4 lokugcina ukwehla kobunzima bezigulana ezityebileyo lufikelele kwindawo yokuqala kunye nenqanaba lesibini lesiphelo.Olu luphando lwesithathu kunye nolwesine oluyimpumelelo lwesigaba III olufunyenwe yiTirzepatide emva kweNtaba ye-1 kunye neNtaba-2.
I-SURMOUNT-3 (i-NCT04657016) yi-multicenter, i-randomized, i-double-blind, i-parallel, isilingo esilawulwa yi-placebo esibhalisa inani elipheleleyo labathathi-nxaxheba be-806 eyenzelwe ukubonisa ukuphakama kwe-Tirzepatide ngaphezu kwe-placebo ngokubhekiselele kwipesenti yokutshintsha kwesisindo emva kokuguqulwa kunye nepesenti ye abathathi-nxaxheba abalahlekelwe ≥5% emva kokungahleliwe kwiiveki ze-72.
Iziphumo zophononongo ze-SURMOUNT-3 zibonise ukuba i-Tirzepatide idibene nazo zonke ii-endpoints, ezizezi ukuba emva kweeveki ze-72 zonyango lwe-dosing, izigulane kwiqela le-Tirzepatide zifumene ipesenti ephezulu yokulahlekelwa kwesisindo ukusuka kwisiseko xa kuthelekiswa ne-placebo, kunye nepesenti ephezulu yezigulane kwiqela le-Tirzepatide. ifumene ipesenti yokulahleka kobunzima obukhulu kune-5%.Idatha ethile yeklinikhi ibonise ukuba izigulane eziphathwe nge-Tirzepatide zilahlekelwe umyinge we-21.1% yesisindo somzimba xa kuthelekiswa ne-placebo;Ukudibanisa kunye nexesha le-12-iveki yokungenelela, izigulane eziphathwe nge-Tirzepatide zilahlekelwe umyinge we-26.6 ekhulwini lobunzima bomzimba wabo.Ukongeza, i-94.4% yezigulane zilahlekelwe ≥5% yobunzima babo kwiqela le-Tirzepatide, xa kuthelekiswa ne-10.7% kwiqela le-placebo.
I-SURMOUNT-4 (i-NCT04660643) i-multicenter, i-randomized, i-double-blind, i-parallel, i-placebo-controlled controlled trial ukubhalisa inani labathathi-nxaxheba be-783 eyenzelwe ukubonisa ukuba i-Tirzepatide yayiphezulu kune-placebo kwipesenti yokuguqulwa kobunzima kwi-88-iveki ye-randomization.
Iziphumo zibonise ukuba emva kwexesha eliphindwe kabini le-37 ~ 88 yeeveki, izigulane kwiqela le-Tirzepatide zalahlekelwa ubunzima ngaphezu kweqela le-placebo.Ngokuphathelele ukhuseleko, akukho zifundo ze-SURMOUNT-3 okanye i-SURMOUNT-4 zabona iimpawu ezintsha zokhuseleko.
Ukusukela ekuqalisweni kwe-Novo Nordisk's blockbuster diet drug Semaglutide, edityaniswa ne-Musk's endorsement, iye yaba yimveliso edumileyo ye-Intanethi kunye nenkosi yokulahleka kwesisindo yangoku.Imfuno yentengiso yokulahleka kobunzima inkulu, kwaye zimbini kuphela iziyobisi ze-GLP-1 zokuncipha kobunzima okwangoku kwintengiso, iLiraglutide kunye neSemaglutide, kodwa iLiraglutide lulungiselelo olufutshane, olungenako ukukhuphisana namalungiselelo athatha ixesha elide malunga nokuthotyelwa kwesigulana. , kunye nehlabathi langoku lokulahlekelwa kwesisindo okwexeshana leSemaglutide.
Kwakhona ukumkani wentsimi ye-GLP-1, uLilly unqwenela ulwandle oluluhlaza kwimarike yokulahlekelwa ubunzima - ngoko uLilly waqalisa umngeni kwaye waqala ukubheja kwiTirzepatide ukuze abambe indawo kwimarike yokunciphisa ubunzima.
I-Tirzepatide yi-GIPR/GLP-1R yee-agonist ezimbini zeveki, i-GIP (i-glucose-exhomekeke kwi-insulin evuselela i-polypeptide) lelinye ilungu lentsapho ye-glucagon peptide, enefuthe lokukhuthaza ukukhutshwa kwe-insulin ngendlela exhomekeke kwi-insulin kunye nokuvuselela ukukhutshwa kweglucagon kwi-hypoglycemic secretion. urhulumente, i-GIPR/GLP-1R i-agonist emibini inokuvelisa ukulawula iswekile yegazi, ukunciphisa umzimba kunye nezinye iziphumo ngokukhuthaza zombini i-GIP kunye ne-GLP-1 iindlela ezisezantsi.I-Tirzepatide ivunyiwe yi-FDA kwi-2022-5 (igama lokuthengisa: i-Mounjaro) ukuze isetyenziswe ngokudibanisa nokutya kunye nokuzivocavoca ukuphucula ukulawulwa kwe-glycemic kubantu abadala abanesifo sikashukela sohlobo lwe-2.
Ixesha lokuposa: Sep-18-2023